GlassScriptPhysician profile
Cathy L Singer
NPI 1295214682
$9,339.05
in general payments reported to CMS, 2019-2025
37 companies · $2,356 in 2025
The $2,356 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $1,638 · 2023: $2,485 · 2024: $2,708 · 2025: $2,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,458 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,458.13 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,601.72 | 2022-2025 | |
| Novo Nordisk INC | $867.98 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $682.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $596.57 | 2022-2025 | Verquvo, Gardasil 9, Belsomra |
| Glaxosmithkline, LLC. | $586.20 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $529.32 | 2023-2025 | Repatha, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $498.05 | 2022-2025 | |
| Astellas Pharma US INC | $497.67 | 2022-2025 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $480.85 | 2022-2025 | Quviviq, Quviviq |
| Astrazeneca Pharmaceuticals LP | $381.89 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.38 | 2022-2025 | Jardiance, Synjardy, Ofev |
| Exact Sciences Corporation | $327.07 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $286.49 | 2024-2025 | Auvelity, Symbravo |
| Scilex Pharmaceuticals INC. | $282.07 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.50 | 2022-2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $125.62 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.09 | 2023-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $87.82 | 2025 | Spravato |
| Biohaven Pharmaceuticals, INC. | $87.80 | 2021 | |
| Esperion Therapeutics, INC. | $80.75 | 2022-2024 | Nexletol |
| Eisai INC. | $79.73 | 2021-2022 | |
| Pfizer INC. | $66.88 | 2023-2025 | |
| Renalytix Ai, INC. | $65.27 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Phathom Pharmaceuticals, INC. | $59.58 | 2024-2025 | Voquezna |
| Abbott Laboratories | $45.67 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Impel Pharmaceuticals INC. | $40.72 | 2023 | Trudhesa |
| Kowa Pharmaceuticals America, INC. | $34.83 | 2022 | |
| Corcept Therapeutics | $33.99 | 2023 | Korlym |
| Viiv Healthcare Company | $33.59 | 2025 | Apretude |
| Biohaven Pharmaceutical Holding Company LTD. | $25.87 | 2022 | |
| Daiichi Sankyo INC. | $23.16 | 2022 | |
| Sumitomo Pharma America, INC. | $21.56 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $20.96 | 2022 | |
| Bausch Health US, LLC | $20.84 | 2024 | Aplenzin |
| Dexcom, INC. | $19.97 | 2023 | Dexcom G6 Transmitter |
| Vivus LLC | $18.72 | 2024 | Qsymia |
| Endo Pharmaceuticals INC. | $17.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.